DIBASIC SODIUM PHOSPHATE, MONOBASIC POTASSIUM PHOSPHATE AND MONOBASIC SODIUM PHOSPHATE tablet

Country: United States

Language: English

Source: NLM (National Library of Medicine)

Active ingredient:

SODIUM PHOSPHATE, DIBASIC, ANHYDROUS (UNII: 22ADO53M6F) (PHOSPHATE ION - UNII:NK08V8K8HR), POTASSIUM PHOSPHATE, MONOBASIC (UNII: 4J9FJ0HL51) (PHOSPHATE ION - UNII:NK08V8K8HR), SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE (UNII: 593YOG76RN) (PHOSPHATE ION - UNII:NK08V8K8HR)

Available from:

Carilion Materials Management

INN (International Name):

SODIUM PHOSPHATE, DIBASIC, ANHYDROUS

Composition:

SODIUM PHOSPHATE, DIBASIC, ANHYDROUS 852 mg

Administration route:

ORAL

Prescription type:

PRESCRIPTION DRUG

Therapeutic indications:

PHOSPHA 250 NEUTRAL increases urinary phosphate and pyrophosphate. As a phosphorus supplement, each tablet supplies 25% of the U.S. Recommended Daily Allowance (U.S. RDA) of phosphorus for adults and children over 4 years of age. TM This product is contraindicated in patients with infected phosphate stones, in patients with severely impaired renal function (less than 30% of normal) and in the presence of hyperphosphatemia. . See DOSAGE AND ADMINISTRATION

Product summary:

NDC:68151-2195-0 in a PACKAGE of 1 TABLETS

Authorization status:

unapproved drug other

Summary of Product characteristics

DIBASIC SODIUM PHOSPHATE, MONOBASIC POTASSIUM PHOSPHATE AND
MONOBASIC SODIUM PHOSPHATE- DIBASIC SODIUM PHOSPHATE, MONOBASIC
POTASSIUM
PHOSPHATE AND MONOBASIC SODIUM PHOSPHATE TABLET
CARILION MATERIALS MANAGEMENT
_Disclaimer: This drug has not been found by FDA to be safe and
effective, and this labeling has not been_
_approved by FDA. For further information about unapproved drugs,
click here._
----------
PHOSPHA 250™ NEUTRAL SUPPLIES 250 MG OF PHOSPHORUS PER TABLET
DESCRIPTION
Each tablet contains 852 mg dibasic sodium phosphate anhydrous, 155 mg
monobasic potassium
phosphate, and 130 mg monobasic sodium phosphate monohydrate. Each
tablet yields approximately 250
mg of phosphorus, 298 mg of sodium (13.0 mEq) and 45 mg of potassium
(1 .1 mEq).
OTHER INGREDIENTS
Purified Water, Lactose Monohydrate, Sodium Starch Glycolate,
Polyvinyl Pyrrolidone, Magnesium
Stearate, Hydroxypropyl methylcellulose, Polyethylene Glycol 400,
Titanium dioxide.
CLINICAL PHARMACOLOGY
Phosphorus has a number of important functions in the biochemistry of
the body. The bulk of the body's
phosphorus is located in the bones, where it plays a key role in
osteoblastic and osteoclastic activities.
Enzymatically catalyzed phosphate-transfer reactions are numerous and
vital in the metabolism of
carbohydrate, lipid and protein, and a proper concentration of the
anion is of primary importance in
assuring an orderly biochemical sequence. ln addition, phosphorus
plays an important role in modifying
steady-state tissue concentrations of calcium. Phosphate ions are
important buffers of the intracellular
fluid, and also play a primary role in the renal excretion of the
hydrogen ion.
Oral administration of inorganic phosphates increases serum phosphate
levels. Phosphates lower
urinary calcium levels in idiopathic hypercalciuria.
In general, in adults, about two thirds of the ingested phosphate in
absorbed from the bowel, most of
which is rapidly excreted into the urine.
INDICATIONS AND USAGE
PHOSPHA 250 NEUTRAL increases urinary phosphate and pyrophospha